用血管素受体阻塞进行预治疗可以防止左心室功能障碍,并阻断与急性心肌梗塞相关的左心室重塑
Hoang Thai1, Lisa Castellano, Elizabeth Juneman
1Cardiology Section, 1-111C, Southern Arizona VA Health Care System Hospital, 3601 S 6th Ave, Tucson, AZ 85723, USA. hoang.thai@med.va.gov
Circulation
|October 25, 2006
概括
在急性心肌梗塞 (MI) 之前先用坎德沙坦进行预治疗,可以改善左心室 (LV) 功能,并防止扩张. 这种治疗还能抑制细胞骨的变化,为减轻MI后的LV重塑提供了潜在的策略.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 急性心肌梗塞 (MI) 导致左心室 (LV) 显著功能障碍和重塑.
- ангиотензин受体阻断剂 (ARBs) 在MI期间被研究其潜在的心脏保护作用.
研究的目的:
- 评估坎德沙坦前期治疗对LV功能和急性心脏病发作后重塑的影响.
- 评估坎德沙坦对LV血液动力学,区域功能和细胞变化的影响.
主要方法:
- 在诱导心脏病发作之前,Sprague-Dawley大鼠在两周内接受了甘地沙坦 (10毫克/公斤/天) 的预治疗.
- 胸功能,压力和尺寸在MI后1,3分钟和6分钟被测量.
- 在LV组织中分析了内皮氧化合成酶和构成性微粒素的水平.
主要成果:
- 坎德萨坦前期治疗显著改善了LV分数缩短和射出分数.
- 乳房静脉腔扩张减弱,乳房静脉静脉缩压降低后MI.
- 虽然LV内皮氧化合成酶水平没有受到影响,但candesartan减弱了构成性微粒素的增加.
结论:
- 在急性心脏病发作之前先用坎德沙坦进行预治疗,可以增强整体LV功能,并防止扩张.
- 康德沙坦通过改变心脏细胞骨架来减弱LV重塑,特别是减弱构成性微管素的增加.
- 该药物对LV血液动力学和区域功能的影响最小.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...